3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Carcinoma, Non-Small-Cell Lung
261
Neoplasms
143
Breast Neoplasms
140
Colorectal Neoplasms
124
Prostatic Neoplasms
94
Neoplasm Metastasis
93
Multiple Myeloma
92
Ovarian Neoplasms
91
Lung Neoplasms
86
Squamous Cell Carcinoma of Head and Neck
62
Pancreatic Neoplasms
62
Recurrence
59
Endometrial Neoplasms
55
Melanoma
52
Small Cell Lung Carcinoma
51
Leukemia, Lymphocytic, Chronic, B-Cell
48
Stomach Neoplasms
47
Carcinoma, Renal Cell
46
Leukemia, Myeloid, Acute
44
Lymphoma, Non-Hodgkin
40
Advanced Solid Tumors
39
Urinary Bladder Neoplasms
37
Triple Negative Breast Neoplasms
36
Parkinson Disease 4, Autosomal Dominant Lewy Body
36
Lymphoma, Large B-Cell, Diffuse
36
Head and Neck Neoplasms
36
Carcinoma, Hepatocellular
35
Lymphoma, Follicular
30
Esophageal Neoplasms
30
Myasthenia Gravis
27
Interventions
exemestane
2
Letrozole
2
ribociclib
1
elacestrant
1
Tamoxifen
1
Leuprolide
1
Goserelin
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms, Male
×
30 days
×
Clear all
NCT05827081
2026-06-03
Adjuvant WIDER
Novartis
Phase 3
Recruiting
1,400 enrolled
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled